Objective:

To discuss the role and impact of biosimilars in the management of retinal diseases, particularly in the context of anti-VEGF therapy.

Approach:

Key Findings:

• Biosimilars are not generic drugs but rigorously evaluated alternatives to biologics.
• Lower costs of biosimilars can significantly improve patient access to treatment.
• Regulatory convergence supports the global acceptance of biosimilars.

Interpretation:

Biosimilars represent a critical advancement in retinal care, addressing both cost and access challenges while maintaining treatment efficacy.

Limitations:

• Regional differences in post-marketing surveillance and healthcare delivery may affect biosimilar integration.
• Continued real-world monitoring is essential to ensure safety and efficacy.

Conclusion:

Biosimilars play a vital role in enhancing the sustainability of retinal disease management, allowing for innovation while addressing cost pressures.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.